Drug Trial Radar · NCT03580369
A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Last checked: Nov 20, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,072
Actual
Start
Oct 17, 2018
Primary completion
Jul 16, 2021
Study completion Jun 14, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to establish safety and efficacy of ligelizumab in adolescent and adult subjects with Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo. The study population consisted of 1,072 male and female subjects aged ≥ 12 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-antihistamines. This was a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.
Conditions
- Chronic Spontaneous Urticaria
Interventions
LigelizumabBiological
Liquid in vial
OmalizumabBiological
Lyophilized powder for solution in vial
PlaceboOther
Liquid in vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult SubjectsTime frame: Baseline, Week 12
- Mean Change From Baseline in UAS7 at Week 12 (Observed Data) of Adolescent Subjects (FAS)Time frame: Baseline, Week 12
Locations
161 sites in 29 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Gilbert, Arizona
Novartis Investigative Site
Litchfield Park, Arizona
Novartis Investigative Site
Scottsdale, Arizona
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Bakersfield, California
Novartis Investigative Site
Huntington Beach, California
Novartis Investigative Site
Long Beach, California
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Greenacres City, Florida
Novartis Investigative Site
Tallahassee, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Boise, Idaho
Novartis Investigative Site
Evansville, Indiana
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Overland Park, Kansas
Novartis Investigative Site
Bangor, Maine
Novartis Investigative Site
Waldorf, Maryland
Novartis Investigative Site
Clarkston, Michigan
Novartis Investigative Site
Ypsilanti, Michigan
Novartis Investigative Site
Plymouth, Minnesota
Novartis Investigative Site
Asheville, North Carolina
Novartis Investigative Site
Cincinnati, Ohio
Novartis Investigative Site
Tulsa, Oklahoma
Novartis Investigative Site
Medford, Oregon
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Pflugerville, Texas
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
South Burlington, Vermont
Novartis Investigative Site
Bahía Blanca, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Capital Federal, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Ciudad Autonoma de Bs As, Buenos Aires, Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Nueve De Julio, Argentina
Novartis Investigative Site
Innsbruck, Austria
Novartis Investigative Site
Vienna, Austria
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.